Key Drivers
- Margin recovery
- Positive cash flow
- Elevated leverage
AIAI Summary
ELAN is evolving into an innovation-led growth and margin-expansion story as Zenrelia and Credelio Quattro drive operating leverage and deleveraging, but investors should require sustained launch adoption, free-cash-flow conversion, and progress toward GAAP profitability given ~3x leverage and thin interest coverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin recovery
- •Positive cash flow
- •Elevated leverage
ELAN's improving quarterly margins and positive free cash flow support recovery potential, but high leverage, weak interest coverage, and intangible-heavy assets warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold momentum
- •Unconfirmed reversal
ELAN remains in a last-month downtrend, with oversold RSI hinting at a possible bounce from $22.40–$22.15 support, but a bullish reversal requires reclaiming $23.15–$23.17.
Price fell about 10.6% from its
Sentiment & News
Key News Insights:
- •Pet Health Momentum
- •Biologics Capacity Expansion
- •Supply Constraint Risk
Elanco's accelerating pet-health innovation, expanded biologics capacity, and supportive investor activity signal improving growth momentum, though Befrena supply constraints remain a near-term watchpoint.
The news is broadly positive for Elanco, supporting growth expectations and investor confidence into third-quarter results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings